Which of the following is used in treatment of chronic thromboembolic pulmonary hypertension?
Which of the following is used in treatment of chronic thromboembolic pulmonary hypertension?
Which of the following is used in treatment of chronic thromboembolic pulmonary hypertension
[A] Vericiguat[B] Riociguat
[C] Rituximab
[D] Alirocumab
Riociguat
Stimulator of soluble guanylate cyclase (sGC). It is used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of the class of sGC stimulators.
Vericiguat
Vericiguat is a medication used to reduce the risk of death and hospitalization in patients with certain types of heart failure. It’s a soluble guanylate cyclase (sGC) stimulator
Rituximab
Rituximab is a targeted cancer drug and antibody therapy used to treat certain types of cancer and autoimmune conditions.
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death.
Alirocumab
Alirocumab is used as a second-line treatment to lower LDL cholesterol for adults who have a severe form of hereditary high cholesterol
Alirocumab works by inhibiting the PCSK9 proteinPCSK9 binds to the low-density lipoprotein receptor (LDLR) (which takes cholesterol out of circulation), and that binding leads to the receptor being degraded, and less LDL cholesterol being removed from circulation. Inhibiting PCSK9 prevents the receptor from being degraded, and promotes removal of LDL cholesterol from circulation.
